Investors
The institutional briefing.
AimwellBio is building the adversarial validation layer beneath AI-generated biopharma intelligence: four independent agents, one source-traced verdict. This page separates what is verifiable today from what is thesis, and says where the rest is shared.

Verified platform data
What the signal corpus contains today.
- Signals indexed
- 4,500
- Intelligence areas
- 9
- Source types
- 4
- Distinct signals
- 4,123
- Last refresh
- October 16, 2026
Operating data from the platform’s own signal manifest, on a scheduled refresh; not a live feed. See the Signals page. Revenue, customer counts and financial statements are not published here; they are shared under NDA.
Thesis · management view, not results
Why the verification layer matters.
- Trust is the barrierBiopharma executives name trust in AI output as a primary barrier to adoption, and general-purpose models can reproduce fabricated claims. A system that earns institutional trust addresses the barrier directly.
- The audit is the productFour independent agents review every brief and a documented verdict follows. The method is published as the Adversarial Validation Standard, so it can be examined by people who did not write it.
- Institutional memory compoundsEach correction, decision and review is retained, so the system’s value to an organization can deepen with use. This is an expectation, not a measured retention figure.
- Infrastructure, not a toolThe intent is to replace scattered, manual intelligence work with a single verified layer. It is early, and the thesis is untested at scale.
Access ladder · current public terms
How customers enter and expand.
| Tier | Price | For |
|---|---|---|
| Observer | Free, after approval | Credentialed professionals |
| Member | $199 / month | Analysts and clinicians running verdicts on a regular cadence |
| Signal | $279 / month | Practitioners who need category monitoring |
| Shield | $449 / month, by request | Professionals who need protected decisions; dossier layer in activation |
| Command | By arrangement | Teams and departments, configured with review |
| Enterprise and sovereign | By arrangement | Multi-department biopharma, institutional and sovereign health |
Public list prices as shown on the pricing page. They are not revenue and say nothing about uptake.
Materials
Request current investor materials.
Full investor deck, financial model and growth roadmap are sent to qualified investors. An NDA is required for full financial materials. Our team verifies and responds, and materials are sent within 1 business day of qualification.
Reading
Public documents.
- The Biotech Intelligence ImperativeWhitepaper on the structural intelligence gap in biopharma.PDF
- The Hallucination Liability CrisisThe case for containment infrastructure.PDF
- The Decision System · Infrastructure BriefingSovereign-grade briefing on the threat, gap and asset framework.PDF
- The Command Layer · Strategic BriefingStrategic briefing for sovereign and enterprise deployments.PDF
- The Adversarial Validation StandardThe published methodology.Read
- Security & complianceWhat is implemented, planned and not claimed.Read
Important information. This page is for information only and is not an offer to sell or a solicitation of an offer to buy any security. It contains forward-looking statements about planned capabilities and expectations, which are not guarantees and involve risks and uncertainties; actual results may differ materially. Nothing here is investment, legal, tax, medical or regulatory advice. AimwellBio is not a registered investment advisor, medical device, or regulatory authority. Aimwell Partners Inc. (OTCID: AIMN).